Literature DB >> 18299670

Acute liver failure in pregnancy: an overview.

V Jayanthi1, N Udayakumar.   

Abstract

Acute liver failure (ALF) in pregnancy is a common challenging clinical problem both in terms of correct diagnosis and management. Acute viral hepatitis is the most common cause of jaundice in pregnancy. The course of acute viral hepatitis is unaffected by pregnancy, except in patients with hepatitis E (HEV), particularly from endemic countries like India, where ALF carries a high mortality. In both HEV infection and herpes simplex infections, maternal and fetal mortality rates are significantly increased. ALF specific to pregnancy including pre-eclampsia, associated with hemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome, acute fatty liver of pregnancy, and hepatic infarction result in increased maternal and fetal mortality if not recognized and acted on early. Early recognition of possible causes and prompt treatment are crucial for successful outcome of ALF in pregnancy. Treatment involves prompt delivery, whereupon the liver disease quickly reverses. This review article addresses the present understanding of ALF in pregnancy reviewing the common causes of ALF and their management in pregnancy.

Entities:  

Mesh:

Year:  2008        PMID: 18299670

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  3 in total

1.  Acute fatty liver of pregnancy: over six months follow-up study of twenty-five patients.

Authors:  Hao-Feng Xiong; Jing-Yuan Liu; Li-Min Guo; Xing-Wang Li
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 2.  Fetal and neonatal health consequences of vertically transmitted hepatitis E virus infection.

Authors:  Lisa J Krain; Jessica E Atwell; Kenrad E Nelson; Alain B Labrique
Journal:  Am J Trop Med Hyg       Date:  2014-01-13       Impact factor: 2.345

Review 3.  Advances in the management of acute liver failure.

Authors:  Da-Wei Wang; Yi-Mei Yin; Yong-Ming Yao
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.